Posted by Michael Wonder on 06 Jun 2022
FDA approves Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), for adults with moderate to severe rheumatoid arthritis
6 June 2022 - Now approved to treat all available Rituxan Indications.
Amgen today announced that the U.S. FDA has approved Riqnbi (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis who have had an inadequate response to one or more tumour necrosis factor antagonist therapies.
